A phase I dose escalation study of LBQ707 (gimatecan) administered orally 5 consecutive days to Japanese patients with advanced solid tumor

Trial Profile

A phase I dose escalation study of LBQ707 (gimatecan) administered orally 5 consecutive days to Japanese patients with advanced solid tumor

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2012

At a glance

  • Drugs Gimatecan (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 28 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 22 Jul 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
    • 03 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top